Some authors have reported that combination therapy might be effective in treating SCLC transformation, likely due to the extensive elimination of EGFR-mutant LUAD cells after the use of EGFR-TKIs and the suppression of EP on EGFR/TP53/RB1 triple mutant sub-clones that resist EGFR-TKI treatment. Here, RB1 is linked to small cell lung carcinoma.